With the recent Hemlibra approval and the gene therapy revolution, we are seeing a much needed race to innovate more effective, long-lasting and curative therapies for hemophilia and acquired bleeding disorders.
As such, the 3rd Hemophilia Drug Development Summit remains dedicated to bringing to patients more effective commercially and clinically translated therapies from small molecules to gene therapies to improve patients' quality of life.
Bringing together over 100 of the world's leading experts and drug developers, we discuss how to develop new therapies for a responsive subset of hemophiliac patients, optimize clinical trial development (setup and management) and discuss the patient/payer paradigm to ensure these novel therapies are affordable and accessible.
With 22+ hours of content, 2 interactive workshops and over 5 hours of networking with key industry leaders, this conference will delve into the challenges of treating each patient subset, as well as hearing the latest advancements in gene therapy and discussing the critical hurdles that need to be overcome to meet the unmet clinical need of all patients.
Join us as we unite drug developers and researchers as we look to the innovation driving the field towards more long-acting and curative therapies to improve patient quality of life.
(+1) 617 455 4188
Drug Developer - Conference + 2 Workshops (A and B) - Earlybird rates available: USD 3497.00,
Drug Developer - Conference + 1 Workshop (A or B) - Earlybird rates available: USD 2898.00
Drug Developer - Conference Only - Earlybird rates available: USD 2299.00,
Drug Developer - Workshops (Individual): USD 599.00
Speakers: Oscar Segurado, Chief Medical Officer, ASC Therapeutics, Robert Sidonio, Assistant Professor, Emory University, Devyn Smith, Chief Operating Officer, Sigilon Therapeutics, John Murphy, Vice President, Discovery Biology, Rare Disease Research Unit, Pfizer, Arjan van der Flier, Senior Principal Scientist, Laboratory Head, Sanofi, Eileen Sawyer, Vice President, Global Medical Affairs, uniQure, Inc